{"name":"TuHURA Biosciences, Inc.","slug":"tuhura-biosciences-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":20532670,"netIncome":-30051977,"cash":3619949,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"IFx-Hu2.0","genericName":"IFx-Hu2.0","slug":"ifx-hu2-0","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"IFx-Hu2.0","genericName":"IFx-Hu2.0","slug":"ifx-hu2-0","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQ01BZWV5WkNsVkZrMVlXc05KemRFNTl2eVNCcllvLTFkel91SFh6SW84bHlWOTBwQ09JWDU4cjJGWFhuMXdWbDctdjZ2dG1iaFBEMnJtbVo5U09rV2d1bDVkcE5ueFRxY1FySWd3SHlaVm9FV0hpZURjRnN4T2p6YTZEVXVsSHI3RTRZb2ZfTEV2dy1tWGM5TEZ3eFpWQ2VfdEd2b19Yai1JMngzUE9COFctUHBPekpia1luMjJ5blVlclVNSTdtZUZEZUZ3REczN1FwU0RNMmtMalBKaUFoOUZ3?oc=5","date":"2026-04-08","type":"pipeline","source":"Sahm","summary":"TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations - Sahm","headline":"TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations","sentiment":"neutral"},{"date":"2026-04-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-02","type":"pipeline","source":"simplywall.st","summary":"TuHURA Biosciences, Inc. (NASDAQ:HURA): Is Breakeven Near? - simplywall.st","headline":"TuHURA Biosciences, Inc. (NASDAQ:HURA): Is Breakeven Near?","sentiment":"neutral"},{"date":"2026-04-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxNbHk1MlgwUERaNk1reGpkZy1ZUlFCYk1IZmFDVWtHaHNTMXozb0lGWkd0WjJnQU9vUUc5N0hiRGY1Y3dvcGxkX3hPM1g4aWJ4U01EUURVR3VleHlqeHJucHBqNFBnUnpxNDR0c0Z0blA5R3h1Z2NsYWN4eFFUUkxGTm0ycU0xY3NzZnluUGpoX3lIRXhINkNDTkxHTEpEdlZuSlZ4Y0RpOEVmX2h6U2RaMTJfYTFTejd0aGZiY2dlOWhwNlZZd2RSQjFROFoyZGI4UnVlc19TVkRRVFdVOHhkd29ZM3JlRnZPNTVsMGNwWXFldw?oc=5","date":"2026-02-17","type":"pipeline","source":"PR Newswire","summary":"TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers - PR Newswire","headline":"TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQalFORUtJa1pBWk13QW9EdUQ4bHJSZDYwc2J4MHFJR0RUN3NGdFF1X05TRnR1QnpzbEhDWjhEbG84NnUxMHd6dHdLQ0RMTWdsVEpmZ1psd1JfbC1Bd1RpRE4tTXNtdWktT1dsYm9ybVY2WjdRZjF4bXM4aTFuTVdzM3NrbUk5UjZxQ1NHSG5sYm4ydExsM01nNTUzYlNpaEpyVWRNMWoyOENOX0lUTWFaZTBOZ21GOGs?oc=5","date":"2026-02-06","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga","headline":"12 Health Care Stocks Moving In Friday's After-Market Session","sentiment":"neutral"},{"date":"2026-01-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPaG9uOWs4YkJYOEJhWUhiRWRwTWdKLUVlVVBzQ0hwUTBlRndMemxKZFVsZERMbnp0LXpybjg3RTgxV0ZoUWxlTGpOYXk5U21PSzNuUW1UQXE4TVdsR0F4T09ZbjdGOHJTSGJrNnVzWFpJLXptVDkxeTBzVUhYSWtXekZoMnFsbHZfLTk0aXZaeGNRa0pUV01rWms2MXlkV2JBLUVpd2pVVzdZc1hzX3doSXlJTm1lcW4yZkxNVQ?oc=5","date":"2025-12-15","type":"pipeline","source":"Stock Titan","summary":"TuHURA Biosciences (NASDAQ: HURA) to issue 1.54M shares after REM-001 CVR milestone - Stock Titan","headline":"TuHURA Biosciences (NASDAQ: HURA) to issue 1.54M shares after REM-001 CVR milestone","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNTzBkdzFnM0lJQUlrOU5ST0loR3phY2xtc1dOUHcxbl92Q0h6V2JlblJncXlRU0xrQ05kMnYxejd1MWM0Ty1GQlZrekktME5ua2MwUDZKelprSUstY3g2V2llcWllcndhbVFCdUQtLTNaWkJELTJKZDUyM3FJN0lXTVR4dlJNQUZWZXBKcHhFZ2h4U0J3MTRWQmFOZkNmcG5YbDNiMEJtT2NzWmJvZnlqTHFPSm9mVlhUN2lacmpkdVB0RE5UMXc?oc=5","date":"2025-12-11","type":"pipeline","source":"PR Newswire","summary":"TuHURA Biosciences Provides Corporate Update Following Recent Financing - PR Newswire","headline":"TuHURA Biosciences Provides Corporate Update Following Recent Financing","sentiment":"neutral"},{"date":"2025-12-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-23","type":"pipeline","source":"simplywall.st","summary":"The recent pullback must have dismayed TuHURA Biosciences, Inc. (NASDAQ:HURA) insiders who own 43% of the company - simplywall.st","headline":"The recent pullback must have dismayed TuHURA Biosciences, Inc. (NASDAQ:HURA) insiders who own 43% of the company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOVkJOUFdXdVk0dDJaaW9QN0NITG13cDROTDBxUS1Bb2NHVEVWY2Z6QmY3U19vNzlsTmhTNUgzMHpITmFKV2JlVVJ3RUhxMUk5cnNyZlFqM0tFc0VNR0FoelNTQjdsMk1SMFZDVFhmMm5pUjlaTC1tVlg0bjk2YzlGRU5SajIzVDZjd0lFNjNSYUJTOWZkeWM5NUlvSml3Um04LW5fMVV6Tm0wdw?oc=5","date":"2025-06-30","type":"pipeline","source":"PR Newswire","summary":"TuHURA Biosciences Completes Acquisition of Kineta - PR Newswire","headline":"TuHURA Biosciences Completes Acquisition of Kineta","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":0,"period":"2025-12-31"},{"value":0,"period":"2024-12-31"},{"value":0,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":20532670,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-30051977,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":3619949,"cashHistory":[],"totalAssets":27353156,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}